Consider the Role of Mounjaro for Type 2 Diabetes
You’ll hear buzz about new injectable Mounjaro (tirzepatide)...the first “twincretin” for type 2 diabetes.
Think of Mounjaro as similar to a glucagon-like peptide-1 (GLP-1) agonist...but it’s also a glucose-dependent insulinotropic polypeptide (GIP) agonist. More twincretins are in the works.
GLP-1 and GIP stimulate insulin release, increase satiety, and decrease glucose production.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote